Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Janet Rader to Endometrial Neoplasms

This is a "connection" page, showing publications Janet Rader has written about Endometrial Neoplasms.

 
Connection Strength
  
 
 
2.534
  
  1. Fowler JM, Brady WE, Grigsby PW, Cohn DE, Mannel RS, Rader JS. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol. 2009 Mar; 112(3):553-7.
    View in: PubMed
    Score: 0.305
  2. Huang YW, Chen JH, Rader JS, Aguilera-Barrantes I, Wang LS. Preventive Effects by Black Raspberries of Endometrial Carcinoma Initiation and Promotion Induced by a High-Fat Diet. Mol Nutr Food Res. 2019 06; 63(12):e1900013.
    View in: PubMed
    Score: 0.155
  3. Shan T, Uyar DS, Wang LS, Mutch DG, Huang TH, Rader JS, Sheng X, Huang YW. SOX11 hypermethylation as a tumor biomarker in endometrial cancer. Biochimie. 2019 Jul; 162:8-14.
    View in: PubMed
    Score: 0.155
  4. Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2019 05; 153(2):335-342.
    View in: PubMed
    Score: 0.154
  5. Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, Bradley WH. Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer. Int J Gynecol Cancer. 2019 01; 29(1):53-59.
    View in: PubMed
    Score: 0.152
  6. Zhang W, Chen JH, Shan T, Aguilera-Barrantes I, Wang LS, Huang TH, Rader JS, Sheng X, Huang YW. miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. Lab Invest. 2018 11; 98(11):1397-1407.
    View in: PubMed
    Score: 0.147
  7. Huang YW, Kuo CT, Chen JH, Goodfellow PJ, Huang TH, Rader JS, Uyar DS. Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol. 2014 May; 133(2):340-5.
    View in: PubMed
    Score: 0.109
  8. Zighelboim I, Schmidt AP, Gao F, Thaker PH, Powell MA, Rader JS, Gibb RK, Mutch DG, Goodfellow PJ. ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol. 2009 Jul 01; 27(19):3091-6.
    View in: PubMed
    Score: 0.078
  9. Tierney RM, Powell MA, Mutch DG, Gibb RK, Rader JS, Grigsby PW. Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. Radiat Med. 2007 Nov; 25(9):439-45.
    View in: PubMed
    Score: 0.071
  10. Zighelboim I, Goodfellow PJ, Gao F, Gibb RK, Powell MA, Rader JS, Mutch DG. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol. 2007 May 20; 25(15):2042-8.
    View in: PubMed
    Score: 0.068
  11. Lin LL, Mutch DG, Rader JS, Powell MA, Grigsby PW. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol. 2007 Jul; 106(1):215-20.
    View in: PubMed
    Score: 0.068
  12. Fayed A, Mutch DG, Rader JS, Gibb RK, Powell MA, Wright JD, Elnaqa I, Zoberi I, Grigsby PW. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):480-4.
    View in: PubMed
    Score: 0.066
  13. McCourt CK, Mutch DG, Gibb RK, Rader JS, Goodfellow PJ, Trinkaus K, Powell MA. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol. 2007 Mar; 104(3):535-9.
    View in: PubMed
    Score: 0.066
  14. Taylor NP, Powell MA, Gibb RK, Rader JS, Huettner PC, Thibodeau SN, Mutch DG, Goodfellow PJ. MLH3 mutation in endometrial cancer. Cancer Res. 2006 Aug 01; 66(15):7502-8.
    View in: PubMed
    Score: 0.064
  15. Wright JD, Powell MA, Herzog TJ, Mutch DG, Rader JS, Gao F, Gibb RK. Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. Gynecol Oncol. 2004 Aug; 94(2):436-41.
    View in: PubMed
    Score: 0.056
  16. Buttin BM, Powell MA, Mutch DG, Babb SA, Huettner PC, Edmonston TB, Herzog TJ, Rader JS, Gibb RK, Whelan AJ, Goodfellow PJ. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004 Jun; 74(6):1262-9.
    View in: PubMed
    Score: 0.055
  17. Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB, Goodfellow PJ. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res. 2004 Jan 15; 10(2):481-90.
    View in: PubMed
    Score: 0.054
  18. Wright JD, Herzog TJ, Mutch DG, Gibb RK, Rader JS, Davila RM, Cohn DE. Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. Gynecol Oncol. 2003 Oct; 91(1):134-8.
    View in: PubMed
    Score: 0.053
  19. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res. 2003 Jun; 9(6):2277-87.
    View in: PubMed
    Score: 0.052
  20. Goodfellow PJ, Buttin BM, Herzog TJ, Rader JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY, Mutch DG. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003 May 13; 100(10):5908-13.
    View in: PubMed
    Score: 0.051
  21. Horowitz N, Pinto K, Mutch DG, Herzog TJ, Rader JS, Gibb R, Bocker-Edmonston T, Goodfellow PJ. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol. 2002 Jul; 86(1):62-8.
    View in: PubMed
    Score: 0.049
  22. Whelan AJ, Babb S, Mutch DG, Rader J, Herzog TJ, Todd C, Ivanovich JL, Goodfellow PJ. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer. 2002 Jun 10; 99(5):697-704.
    View in: PubMed
    Score: 0.048
  23. Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer. 2002 Jun 01; 94(11):2941-52.
    View in: PubMed
    Score: 0.048
  24. Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ. Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2002 Feb; 84(2):241-4.
    View in: PubMed
    Score: 0.047
  25. Cohn DE, Mutch DG, Herzog TJ, Rader JS, Dintzis SM, Gersell DJ, Todd CR, Goodfellow PJ. Genotypic and phenotypic progression in endometrial tumorigenesis: determining when defects in DNA mismatch repair and KRAS2 occur. Genes Chromosomes Cancer. 2001 Dec; 32(4):295-301.
    View in: PubMed
    Score: 0.047
  26. Cohn D, Mutch D, Elbendary A, Rader J, Herzog T, Goodfellow P. No evidence for BCL10 mutation in endometrial cancers with microsatellite instability. Hum Mutat. 2001 Feb; 17(2):117-21.
    View in: PubMed
    Score: 0.044
  27. Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer. 2000 Oct 15; 89(8):1758-64.
    View in: PubMed
    Score: 0.043
  28. Cohn DE, Basil JB, Venegoni AR, Mutch DG, Rader JS, Herzog TJ, Gersell DJ, Goodfellow PJ. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol. 2000 Oct; 79(1):101-6.
    View in: PubMed
    Score: 0.043
  29. Basil JB, Swisher EM, Herzog TJ, Rader JS, Elbendary A, Mutch DG, Goodfellow PJ. Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability. Gynecol Oncol. 1999 Sep; 74(3):395-9.
    View in: PubMed
    Score: 0.040
  30. Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, Goodfellow PJ. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer. 1999 Jan 01; 85(1):119-26.
    View in: PubMed
    Score: 0.038
  31. Rader JS, Neuman RJ, Brady J, Babb S, Temple S, Kost E, Mutch DG, Herzog TJ. Cancer among first-degree relatives of probands with invasive and borderline ovarian cancer. Obstet Gynecol. 1998 Oct; 92(4 Pt 1):589-95.
    View in: PubMed
    Score: 0.037
  32. Swisher EM, Mutch DG, Herzog TJ, Rader JS, Kowalski LD, Elbendary A, Goodfellow PJ. Analysis of MSH3 in endometrial cancers with defective DNA mismatch repair. J Soc Gynecol Investig. 1998 Jul-Aug; 5(4):210-6.
    View in: PubMed
    Score: 0.037
  33. Kowalski LD, Mutch DG, Herzog TJ, Rader JS, Goodfellow PJ. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer. 1997 Mar; 18(3):219-27.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.